胸腔积液中环氧化酶-2与血管内皮生长因子的表达及临床意义

doi:10.3877/cma.j.issn.1674-0785.2017.14.002

中华临床医师杂志(电子版) ›› 2017, Vol. 11 ›› Issue (14) : 2019 -2022. doi: 10.3877/cma.j.issn.1674-0785.2017.14.002

所属专题：文献；

临床论著

胸腔积液中环氧化酶-2与血管内皮生长因子的表达及临床意义

赵方正¹, 郑新华², 黄传君², 邓鹏辉³, 宫晓丹⁴, 张才擎⁵^,^†(

)

^1. 250355　济南，山东中医药大学2015级研究生；250014　济南，山东省千佛山医院呼吸内科
^2. 250355　济南，山东中医药大学2015级研究生
^3. 271000　泰安，泰山医学院
^4. 250014　济南，山东大学医学院
^5. 250014　济南，山东省千佛山医院呼吸内科

收稿日期:2017-03-07 出版日期:2017-07-15
通信作者: 张才擎
基金资助:
山东省自然科学基金(ZR2013HM046)

Clinical significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in pleural effusion

Fangzheng Zhao¹, Xinhua Zheng², Chuanjun Huang², Penghui Deng³, Xiaodan Gong⁴, Caiqing Zhang⁵^,^†()

^1. Shandong University of Traditional Chinese Medicine, Jinan 250355, China; Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital, Jinan 250014, China
^2. Shandong University of Traditional Chinese Medicine, Jinan 250355, China
^3. Taishan Medical University, Taian 271000, China
^4. School of Medicine, Shandong University, Jinan 250014, China
^5. Department of Respiratory Medicine, Shandong Provincial Qianfoshan Hospital, Jinan 250014, China

Received:2017-03-07 Published:2017-07-15
Corresponding author: Caiqing Zhang
About author:
Corresponding author: Zhang Caiqing, Email: freezcq66@163.com

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

赵方正, 郑新华, 黄传君, 邓鹏辉, 宫晓丹, 张才擎. 胸腔积液中环氧化酶-2与血管内皮生长因子的表达及临床意义[J/OL]. 中华临床医师杂志(电子版), 2017, 11(14): 2019-2022.

Fangzheng Zhao, Xinhua Zheng, Chuanjun Huang, Penghui Deng, Xiaodan Gong, Caiqing Zhang. Clinical significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in pleural effusion[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(14): 2019-2022.

目的

通过胸腔积液中环氧化酶-2（COX-2）及血管内皮生长因子（VEGF）含量的测定，探讨COX-2、VEGF对良恶性胸腔积液的鉴别诊断价值及意义。

方法

选取于2015年6月至2016年8月在山东省千佛山医院就诊并确诊的48例恶性胸腔积液、10例良性胸腔积液，酶联免疫吸附法（ELISA法）测定胸腔积液中COX-2、VEGF的表达水平，比较COX-2、VEGF在良恶性胸腔积液中表达的差异。

结果

48例恶性胸腔积液及10例良性胸腔积液中COX-2、VEGF表达量与性别、年龄无明显关系（P>0.05）。恶性胸腔积液中COX-2、VEGF表达量为（788.04±128.85）U/L、（365.27±80.63）ng/L，良性胸腔积液中COX-2、VEGF表达量为（366.92±41.08）U/L、（114.67±15.69）ng/L，恶性胸腔积液中COX-2、VEGF表达水平显著高于良性胸腔积液，差异具有统计学意义（P<0.001）。

结论

恶性胸腔积液中COX-2、VEGF的表达显著高于良性胸腔积液，有望成为良恶性胸腔积液鉴别诊断的有效指标。

关键词: 环氧化酶-2, 血管内皮生长因子, 胸腔积液, 肿瘤

Objective

To assess the significance of COX-2 and VEGF in the differential diagnosis of benign and malignant pleural effusions by detecting their levels in pleural effusion.

Methods

Fifty-eight cases of pleural effusion were collected at our hospital, including 48 cases of malignant pleural effusion and 10 cases of benign pleural effusion. Expression levels of COX-2 and VEGF in pleural effusions were detected by ELISA and compared between benign and malignant pleural effusions.

Results

The expression levels of COX-2 and VEGF had no significant association with gender or age in both 48 cases of malignant pleural effusion and 10 cases of benign pleural effusion (P>0.05). The average COX-2 and VEGF levels were (788.04 ± 128.85) U/L and (365.27 ± 80.63) ng/L, respectively, in the malignant pleural effusion group, and the corresponding values in the benign pleural effusion group were (366.92 ± 41.08) U/L and (114.67 ± 15.69) ng/L. COX-2 and VEGF levels in malignant pleural effusion were significantly higher than those in benign pleural effusion (P<0.001).

Conclusion

COX-2 and VEGF expression levels are higher in malignant pleural effusion than in benign pleural effusion, and they may serve as prognostic factors to distinguish between benign and malignant pleural effusions.

Key words: Cyclooxygenase-2, Vascular endothelial growth factor, Pleural effusion, Tumor

表1 2组胸腔积液中COX-2、VEGF含量的比较（±s）

组别	例数	COX-2（U/L）	VEGF（?ng?/L）
试验组	48	788.04±128.85	365.27±80.63
对照组	10	366.92±41.08	114.67±15.69
P值	?	＜0.05	＜0.05

表1 2组胸腔积液中COX-2、VEGF含量的比较（±s）

组别	例数	COX-2（U/L）	VEGF（?ng?/L）
试验组	48	788.04±128.85	365.27±80.63
对照组	10	366.92±41.08	114.67±15.69
P值	?	＜0.05	＜0.05

表2 不同肿瘤组胸腔积液COX-2、VEGF含量的比较（±s）

肿瘤类型	例数	COX-2（U/L）	VEGF（?ng?/L）	r值	P值
肺癌	23	847.21±131.89^a	403.12±89.23^a	0.89	＜0.05
乳腺癌	11	759.35±97.16^a	330.22±38.57^a	0.78	＜0.05
肝癌	6	710.33±95.38^a	307.05±57.93^a	0.91	＜0.05
胃癌	8	676.89±62.74^a	365.98±39.12^a	0.77	＜0.05
结核性胸膜炎	10	368.52±39.97	115.03±16.25	?	?

表2 不同肿瘤组胸腔积液COX-2、VEGF含量的比较（±s）

肿瘤类型	例数	COX-2（U/L）	VEGF（?ng?/L）	r值	P值
肺癌	23	847.21±131.89^a	403.12±89.23^a	0.89	＜0.05
乳腺癌	11	759.35±97.16^a	330.22±38.57^a	0.78	＜0.05
肝癌	6	710.33±95.38^a	307.05±57.93^a	0.91	＜0.05
胃癌	8	676.89±62.74^a	365.98±39.12^a	0.77	＜0.05
结核性胸膜炎	10	368.52±39.97	115.03±16.25	?	?

[1]	阮光强，王羡强，陈国军, 等. 胸水中VEGF、TNF-α的检测对良恶性胸水的鉴别诊断意义 [J]. 现代生物医学进展, 2012, 12(15):2952-2953,2958.
[2]	Antonangelo L, Sales RK, Corá AP, et al. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results [J]. Curr Oncol, 2015, 22(5):336-341.
[3]	Cheng F, Wang Q, Zhong D. Value of cell block in the diagnosis of malignant pleural effusion [J]. Zhongguo Fei Ai Za Zhi, 2015, 18(10):652-655.
[4]	Wasilewicz MP, Kołodziej B, Bojułko T, et al. Expression of cyclooxygenase-2 in colonic polyps [J]. Pol Arch Med Wewn, 2010, 120(9):313-320.
[5]	Fiorelli A, Vicidomini G, Di Domenico M, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications [J]. Interact Cardiovasc Thorac Surg, 2011, 12(3):420-424.
[6]	徐杰，齐大亮，李绪斌, 等. 重组人血管内皮抑制素联合化疗治疗非小细胞肺癌恶性胸腔积液的疗效观察 [J]. 中国肿瘤临床, 2014, 41(24):1573-1576.
[7]	Hooper C, Lee YC, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010 [J]. Thorax, 2010, 65(2):4-17.
[8]	Qu L, Liu B. Cyclooxygeanse-2 promotes metastasis in osteosarcoma [J]. Cancer Cell Int, 2015, 15(1):69-75.
[9]	Singh-Ranger G, Giordano P. A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer [J]. Int J Colorectal Dis, 2009, 24(7):863.
[10]	Lobo PK, Vu L, Chan SK, et al. Predictive utility of cyclooxygenase-2 expression by colon and rectal cancer [J]. Am J Surg, 2014, 207(5):712-716.
[11]	Gou HF, Chen XC, Zhu J, et al. Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications [J]. J Exp Clin Cancer Res, 2011, 30(9):14-18.
[12]	Elzagheid A, Emaetig F, Alkikhia L, et al. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer [J]. Anticancer Res, 2013, 33(8):3137-3143.
[13]	Weidner N. Introtumor microvessel density as a prognostic factor in cancer [J]. Am J Pathol, 1995, 147(1):9-19.
[14]	Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in lung cancer [J]. Cancer Chemother Pharmacol, 2013, 72(6):1169-1181.
[15]	Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor(vascular endothelial growth factor)and its receptors in adenocarcinomas of the gastrointestinal tract [J]. Cancer Res, 1993, 53(19):4727-4735.
[16]	Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation [J]. Clin Cancer Res, 2000, 6(3):957-965.
[17]	Christoph B. Transforming growth factor-β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular cancer cell [J]. Cancer Res, 2003, 63(5):1083-1092.
[18]	Yuan A, Yu CJ, Shun CT, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients [J]. Int J Cancer, 2005, 115(4):545-555.

[1]	韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[2]	李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[3]	陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[4]	许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5]	李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6]	刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[7]	任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[8]	赵丽霞, 王春霞, 陈一锋, 胡东平, 张维胜, 王涛, 张洪来. 内脏型肥胖对腹腔镜直肠癌根治术后早期并发症的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 35-39.
[9]	吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[10]	周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[11]	常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[12]	高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13]	徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[14]	王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[15]	李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in pleural effusion

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in pleural effusion